Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from th...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Perez, Edith A., Dueck, Amylou C., McCullough, Ann E., Reinholz, Monica M., Tenner, Kathleen S., Davidson, Nancy E., Gralow, Julie, Harris, Lyndsay N., Kutteh, Leila A., Hillman, David W., Jenkins, Robert B., Chen, Beiyun
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2012
Предметы:
Brief Communication
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3260130/
https://ncbi.nlm.nih.gov/pubmed/22138096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djr490
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы